Cognitive Flexibility and Creativity in People with Parkinson*s: A Pilot Study Exploring the Influence of Dopaminergic Regulation on Cognitive Flexibility and Creativity, with an Emphasis on Visual Art

Cognitive Flexibility and Creativity in People with Parkinson*s: A Pilot Study Exploring the Influence of Dopaminergic Regulation on Cognitive Flexibility and Creativity, with an Emphasis on Visual Art - Cognitive Flexibility and Creativity in People with Parkinson*s

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON56761

Enrollment

Registered

2023-11-01

Start date

2025-03-20

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease Parkinson's disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - 18 years of age or older - diagnosed with idiopathic Parkinson*s disease - willingness to participate in the intervention program and attend all  scheduled test sessions  

Exclusion criteria

Exclusion criteria: - received deep brain stimulation (brain surgery) - severe co-morbidities or other additional neurodegenerative diseases or disorders (except PD/medication related mood disorders) - legally incompetent adults who are unable to provide informed consent or manage their own affairs. - requirement for full-time nursing care. - absence of written informed consent from the participant.

Design outcomes

Primary

Measure	Time frame
Primary outcome 1. Applicability and Feasibility: Given the potential symptom-related confounders in PD, such as severe motor issues (tremor, dystonia) and impulsive rejection of conducting tasks, it is critical to determine whether the tasks and the entire battery are practical and feasible. 2. Face Validity Assessment: This pilot will involve subjective evaluation by a research team (including psychologists) through observing participants during the tasks to assess if the tests cover the concept they purport to measure, thus gauging the face validity. 3. External Validity Assessment: We intend to visit people in their homes and interview both participants and caregivers, considering participants* daily life circumstances, issues, and behaviour to ensure the external validity (considering widening the results to their homes) of our findings.	—

Measure

Time frame

Primary outcome 1. Applicability and Feasibility: Given the potential symptom-related confounders in PD, such as severe motor issues (tremor, dystonia) and impulsive rejection of conducting tasks, it is critical to determine whether the tasks and the entire battery are practical and feasible. 2. Face Validity Assessment: This pilot will involve subjective evaluation by a research team (including psychologists) through observing participants during the tasks to assess if the tests cover the concept they purport to measure, thus gauging the face validity. 3. External Validity Assessment: We intend to visit people in their homes and interview both participants and caregivers, considering participants* daily life circumstances, issues, and behaviour to ensure the external validity (considering widening the results to their homes) of our findings.

—

Secondary

Measure	Time frame
The secondary objective is to get first insights into potential relationships of the explored outcomes of the test battery. Within this small cohort, investigations into the relationships between PD, dopamine, creativity, cognitive flexibility, and PD/dopaminergic-induced mood and behavioural changes are considered explorative research.	—

Countries

Netherlands

Contacts

Public ContactBTM Spee

Radboud Universitair Medisch Centrum

info@onderzoek-parkinson.nl0248080141

Outcome results